Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Roferon-A

(Interferon Alfa-2a)

Phase 3Small molecule

Interferon Alfa-2a is used to treat certain cancers like leukemia and lymphoma, and also helps fight chronic hepatitis C by boosting the body's immune system to attack infected cells and tumors.[1] Roferon-A is currently being investigated across 16 indications[3], with its most advanced program in Phase 3.[1]

Roferon-A is one of 483 small molecule programs targeting HIV infection. It is currently in Phase 3.

16

Indications

21

Total Trials

0

Active Trials

482

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Kidney CancerActive, not recruiting

LymphomaActive, not recruiting

Hairy Cell LeukemiaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Chronic HepatitisActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

MelanomaActive, not recruiting

Ovarian CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Hairy Cell LeukemiaPhase 2

Active, not recruiting

Metastatic MelanomaPhase 2

Active, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Renal Cell CarcinomaPhase 3

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Roferon-A

Blenoxane

SSequus Pharmaceuticals

Velban

EEastern Cooperative Oncology Group

Zofran

Norvir

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Kenalog

BBausch Health Americas, Inc.

Nuvigil

NNuvo Research GmbH

Systemic Therapy

Bristol-Myers Squibb

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis3 trials

Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease

Completed·NNational Taiwan University Hospital·Phase 4·NCT00172809·50 enrolled

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Completed·UUniversity Hospital, Geneva·Phase 2·NCT00433069·5 enrolled

Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·N/A·NCT03733652·100 enrolled

Kaposi's sarcoma3 trials

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000725·56 enrolled

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000687·60 enrolled

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001113·48 enrolled

HIV infection2 trials

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000764·98 enrolled

A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000754·60 enrolled

Hepatitis C2 trials

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00008463·132 enrolled

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

Completed·TTaiGen Biotechnology Co., Ltd.·Phase 2·NCT02340962·25 enrolled

Renal Carcinoma1 trial

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

Completed·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 3·NCT00502034·310 enrolled

10 more indications

Metastatic Renal Cell Cancer1 trial

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00520403·25 enrolled

Children1 trial

The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000967·52 enrolled

Induction Therapy1 trial

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Completed·FFoundation for Liver Research·Phase 3·NCT00381953·33 enrolled

Kidney Cancer1 trial

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00719264·365 enrolled

Ovarian Cancer1 trial

Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer

Unknown status·LLeiden University Medical Center·Phase 1/2·NCT04072263·12 enrolled

Uveitis1 trial

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Completed·PPeking Union Medical College Hospital·Phase 3·NCT03209219·28 enrolled

Renal Cell Carcinoma1 trial

A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Completed· Roche logo

Roche·Phase 2·NCT00796757·146 enrolled

HIV1 trial

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000696·48 enrolled

Treatment1 trial

To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.

Unknown status·SSun Yat-sen University·N/A·NCT03771677·400 enrolled

Pilot Study1 trial

Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines

Terminated·—·Phase 2·NCT02159482·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Interferon Alfa-2a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Interferon Alfa-2a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Interferon Alfa-2a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interferon Alpha/beta Receptor Agonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Related News